Konstantinos Syrigos to Treatment Outcome
This is a "connection" page, showing publications Konstantinos Syrigos has written about Treatment Outcome.
Connection Strength
0.137
-
Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study. In Vivo. 2021 Jan-Feb; 35(1):653-661.
Score: 0.033
-
The Role of Tinzaparin in Oncology. Clin Appl Thromb Hemost. 2018 Jul; 24(5):697-707.
Score: 0.026
-
Pulmonary hypertension after pneumonectomy for lung cancer. Asian Cardiovasc Thorac Ann. 2014 Nov; 22(9):1072-9.
Score: 0.021
-
An open label trial of anakinra to prevent respiratory failure in COVID-19. Elife. 2021 03 08; 10.
Score: 0.008
-
Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. JAMA Netw Open. 2020 06 01; 3(6):e2013136.
Score: 0.008
-
A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer. Lung Cancer. 2019 10; 136:52-56.
Score: 0.007
-
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. JAMA Oncol. 2018 09 01; 4(9):1189-1197.
Score: 0.007
-
Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. Med Oncol. 2018 May 31; 35(7):101.
Score: 0.007
-
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG). J Neurooncol. 2017 Sep; 134(2):443-451.
Score: 0.006
-
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer. Lung Cancer. 2017 10; 112:126-133.
Score: 0.006
-
Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. Lung Cancer. 2017 07; 109:101-108.
Score: 0.006